Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Defence Therapeutics Inc. (DTC) has given an update on its antibody-drug conjugate (ADC) programs undergoing development using its candidate drug, Accum
  • Defence and the Curie Institute are working on an efficacy study of the drug in a patient-derived model for breast cancer
  • Collaboration with the HUS Comprehensive Cancer Center has been extended to test Accum against other treatments for fighting cancer in tumors
  • The Institut de Recherche en Cancérologie de Montpellier (IRCM) and Defence are working on two in vivo studies in hopes they can increase the drug treatment ratio
  • Defence Therapeutics Inc. (DTC) is unchanged trading at $2.00 per share as of 9:41 a.m. ET

Defence Therapeutics (DTC) has provided an update on its antibody-drug conjugate (ADC) programs undergoing development using its candidate drug, Accum.

According to Defence, the Curie Institute, one of the collaborators, is performing an efficacy study of Accum-T-DM1 (antibody) ADC in a patient-derived model for breast cancer.

After which, a comparison study will analyze the safety of T-DM1 against Accum T-DM1 in mice. Defence is expecting to see the study’s results sometime between its third and fourth quarter.

T-DM1, under the brand Kadcyla, is used to treat women with metastatic HER2-positive breast cancer. Defence stated this study is meant to prove that the current treatment may be improved using the Accum technology through the drug’s delivery to the tumour cells.

Defence commented it is extending its collaboration with the HUS Comprehensive Cancer Center. The collaboration includes comparisons of T-DM1 versus Accum-T-DM1 versus co-treatment of AccuTOX variants by injecting it within a tumour. Results from these studies are expected sometime at the end of this year.

The Institut de Recherche en Cancérologie de Montpellier (IRCM), is executing in vivo studies using AccumTM with radio-immuno-therapeutic combinations. Defence hopes to strengthen the ratio of the drug while minimizing side effects. Results are expected to be released in the second half of this year.

Defence stated it is also working with WASSC Technologies to develop a new small molecule for ADC application. Toxicity results of variants are expected to arrive during the third quarter.

Defence Therapeutics Inc. (DTC) is unchanged trading at $2.00 per share as of 9:41 a.m. ET.

More From The Market Herald
Emerald Health Therapeutics Inc. - Director & Chairman, Jim Heppell.

" Emerald Health (CSE:EMH) shareholders approve merger

Emerald Health Therapeutics (EMH), has received shareholders’ approval for the proposed plan of arrangement with Skye Bioscience Inc.
Mydecine Innovations Group - CEO, Josh Bartch.

" Mydecine (NEO:MYCO) raises $244K and shifts management team

Mydecine Innovations Group (MYCO) has signed a common share subscription agreement with a third-party investor for proceeds up to $244,99.50.
PharmaDrug - CEO, Daniel Cohen

" PharmaDrug (CSE:PHRX) completes milestone to support cGMP production of PD-001

PharmaDrug (PHRX) has laid the groundwork to support cGMP production of cepharanthine-2HCL for use in the drug product production of PD-001.

" Hemostemix (TSXV:HEM) announces $1.5M non-brokered private placement

Hemostemix (HEM) has announced a non-brokered private placement of up to 5 million units for gross proceeds of up to $1.5 million.